Previous Article | Next Article 
Molecular and Cellular Biology, August 2001, p. 5447-5458, Vol. 21, No. 16
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.16.5447-5458.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Regulation of Id Gene Expression by Type I Insulin-Like Growth
Factor: Roles of STAT3 and the Tyrosine 950 Residue of the
Receptor
Marco
Prisco,
Francesca
Peruzzi,
Barbara
Belletti, and
Renato
Baserga*
Kimmel Cancer Center, Thomas Jefferson
University, Philadelphia, Pennsylvania 19107
Received 20 December 2000/Returned for modification 6 April
2001/Accepted 16 May 2001
 |
ABSTRACT |
Id proteins are known to play important roles in the proliferation
and differentiation of many cell types. The type 1 insulin-like growth
factor receptor (IGF-IR), activated by its ligand, induces the
differentiation of 32D IGF-IR cells, a murine hematopoietic cell line,
expressing a human IGF-IR. Expression in 32D IGF-IR cells of a dominant
negative mutant of Stat3 (DNStat3) inhibits IGF-I-mediated
differentiation. DNStat3 causes a dramatic increase in Id2 gene
expression. This increase, however, is IGF-I dependent and is abrogated
by a mutation at tyrosine 950 of the IGF-IR. These results indicate
that in 32D cells, the IGF-IR regulates the expression of the Id2 gene
and that this regulation is modulated by both positive and negative
signals. Our results also suggest that in this model, Id2 proteins
influence the differentiation program of cells but are not sufficient
for the full stimulation of their proliferation program.
 |
INTRODUCTION |
The Id family of helix-loop-helix
proteins are known to form heterodimers with similar proteins, mostly
transcriptional activators, composed of a basic region and a
helix-loop-helix region (57). Because the Id proteins lack
a DNA binding region, these heterodimers cannot bind to DNA. The Id
proteins therefore function as negative regulators of basic
helix-loop-helix proteins through the formation of inactive
heterodimers (6, 57). MyoD is the best-known transcription
factor inhibited by Id proteins, but other genes important in
neurogenic and hematopoietic differentiation are also inhibited
(46). There are at least four Id proteins, but there is
evidence in the literature the Id1 and Id3 are overlapping, while
expression of Id4 is limited to specific tissues (32, 41).
Id gene expression varies during mouse development (32) and is markedly increased in proliferating cells, in cycling cells, and
in tumor cell lines (2, 6). Id gene expression has been implicated in the G1-to-S transition (28, 46).
High levels of Id gene expression inhibit the differentiation of a
variety of cell types (6, 36, 40), including mammary cell
differentiation (16). Id expression is repressed in
senescent cells (28), and the Id1 protein has been claimed
to delay senescence of primary human keratinocytes (1,
45). The Id1 protein promotes mammary epithelial cell invasion
(17) and increases the aggressive phenotype of human
breast cancer cells (39). The Id2 protein has been reported to inhibit differentiation and enhance cellular proliferation by associating with the retinoblastoma protein (30). More
recently, it has been reported that the Id2 promoter is the target of
the proto-oncogene N-myc in neuroblastoma cells
(38). Id proteins are also required for angiogenesis and
vascularization of tumor xenografts (41).
The dual role of Id proteins in proliferation and differentiation has
prompted us to examine their regulation by the type 1 insulin-like
growth factor receptor (IGF-IR), which also sends a dual signal. The
IGF-IR, activated by its ligands, sends an unambiguous mitogenic signal
in many cell types, such as fibroblasts and epithelial cells
(53). However, in other cell types, IGF-I (or IGF-II) can
stimulate either proliferation or differentiation or both
(3). We have studied these contradictory signals of the
IGF-IR (mitogenesis versus differentiation) in 32D cells, a murine
hematopoietic cell line, which undergo apoptosis within 24 h after
withdrawal of interleukin-3 (IL-3) (51, 60, 61). 32D cells
have low levels of IGF-I and insulin receptors and do not express IRS-1
or IRS-2 (60, 62), which are important substrates for both
receptors. 32D cells expressing a human IGF-IR cDNA (32D IGF-IR cells)
survive in the absence of IL-3 and, with the addition of IGF-I, grow
exponentially for about 48 h (18, 48, 55, 59). After
48 h, the cells begin to differentiate along the granulocytic
pathway and eventually decrease in number (60). This
sequence of events is not unusual in hematopoietic cells, where
induction of differentiation requires a short but intense period of
cell proliferation (8, 61, 63). This dual response has
been interpreted as indicating that differentiating growth factors send
two signals, one for proliferation and one for differentiation, with
the latter eventually prevailing.
We have asked whether signaling from the IGF-IR can regulate the
expression of Id genes. If Id gene expression were to be regulated by
the IGF-IR, it would be interesting to identify the domain(s) of the
IGF-IR that regulates it. Specifically, we wished to investigate Id
gene expression in 32D-derived cells, which either differentiate or
grow indefinitely in the absence of IL-3. For differentiation, 32D
IGF-IR cells (see above) are the obvious choice, since they
differentiate under the control of IGF-I (60). To inhibit
the differentiation of 32D IGF-IR cells in the absence of IRS-1, we
introduced into these cells a dominant negative mutant of Stat3
(DNStat3), which has been reported to inhibit granulocyte colony-stimulating factor (G-CSF)-induced differentiation of 32D cells
(15, 54).
We find that expression of DNStat3 in 32D IGF-IR cells abrogates
IGF-I-mediated differentiation. In fact, the cells become transformed,
by stringent criteria. Using this strategy, we report that Id2 RNA
expression is regulated by the IGF-IR, with a dramatic up-regulation in
cells expressing DNStat3. There are also changes in Id1 RNA levels, but
these are not as clear as in the case of Id2 gene expression. A
mutation at tyrosine 950 (Y950F) of the IGF-IR abrogates the
up-regulation of Id2 gene expression, regardless of the presence or
absence of DNStat3. IGF-I-mediated Id2 gene expression is also
inhibited by inhibitors of the mitogen-activated protein kinase
(MAPK) or phosphatidylinositide 3-kinase (PI3K) pathways. These
results are compatible with a hypothesis in which Y950 of the IGF-IR,
in 32D cells, sends a dual signal. One signal (through the MAPK and
PI3K pathways) induces up-regulation of Id2 gene expression.
Simultaneously, Y950 sends (through Stat3) a signal that represses Id2
gene expression. In this model, the role of Stat3 is to inhibit Id2
gene activation. The role of Id2 gene expression in proliferation
versus differentiation cannot be defined at this point, especially
since the data in the literature are sometimes contradictory. However,
at least in our model system, up-regulation of Id2 gene expression is
correlated with inhibition of the differentiation program.
Overexpression of Id2 in 32D IGF-IR cells also inhibits the
differentiation program of these cells (as determined by
myeloperoxidase RNA levels). However, Id2 overexpression is not
sufficient for transformation of 32D IGF-IR cells, indicating that
DNStat3 sends additional signals, above and beyond the up-regulation of
Id2 gene expression.
 |
MATERIALS AND METHODS |
Plasmids, cell lines, and retroviral infection.
The Stat3
Y705F cDNA with a FLAG tag at the 3' end, kindly provided by J. E. Darnell, Jr. (The Rockefeller University, New York, N.Y.), was excised
from pRcStat3Y705F and inserted into the pMSCVpac retroviral vector
(29) to generate pMSCVpac DN Stat3 Y705F.
32D cells and 32D-derived cells were cultured in RPMI 1640 medium with
10% fetal bovine serum (FBS) and 10% WEHI cell conditioned medium as
a source of IL-3. 32D, 32D IGF-IR, 32D IR, and 32D Y950F cells were
previously described and characterized (18, 48, 60). These
cell lines were transduced with pMSCVpac DN Stat3 Y705F to generate
mixed populations of 32D DN Stat3, 32D IGF-IR/DN Stat3, 32D IR/DN
Stat3, and 32D Y950F/DN Stat3 cells. Selection was carried out with 1.5 µg of puromycin per ml. The same strategy was used to generate from
32D IGF-IR cells cell lines stably expressing the Id2 cDNA (see
"Northern blots" below). Selection was again with puromycin. The
infection method was described by Prisco et al. (49). In
one experiment, Id2 RNA levels were measured in quiescent or stimulated
R600 mouse embryo fibroblasts, an NIH 3T3-like cell line
(49).
Growth, survival, and differentiation.
Cells were washed
three times with Hanks' balanced salt solution (HBSS) and seeded at a
density of 5 × 104 cells/35-mm plate in 2 ml of RPMI
1640 medium supplemented with 10% FBS with or without 50 ng of IGF-I
or insulin (GIBCO-BRL) per ml or 10% WEHI cell conditioned medium. The
cells were counted by trypan blue exclusion (Life Technology) at the
indicated times after IL-3 withdrawal. For analysis of differentiation,
exponentially growing cells were collected, washed three times with
HBSS, and seeded (5 × 104 cells/ml) in RPMI 1640 medium containing 10% FBS and 50 ng of IGF-I per ml. After 96 h,
viable cells were counted by trypan blue exclusion (Life Technology)
and cytospins were used for the morphological analysis as described by
Valentinis et al. (60). Differentiation was expressed as
the percentage of bands and polymorphonuclear cells in the total number
of scored cells. Treatment with rapamycin was carried out with the
concentrations and the modalities previously described
(60).
Northern blots.
Cells were seeded under the same conditions
used for growth analysis. At the indicated time points, the cells were
collected and total RNA was extracted with an RNeasy mini kit (Qiagen). In some experiment, cells were washed, treated with the inhibitor PD98059 (Calbiochem) or LY94002 (Biomol) at 50 µM for 15 min in RPMI
1640 medium containing 10% FBS or left untreated, and, after being
washed, seeded (5 × 104 cells/ml) in complete medium
or in medium supplemented with 10% FBS and 50 ng of IGF-I per ml for
the indicated times.
An 8-µg portion of total RNA for each sample was run on a 1%
agarose-formaldehyde gel, blotted onto a nylon membrane, and
hybridized with a 1.3-kb Id2 cDNA obtained from pLXSN Id2 plasmid
or
with a 1.1-kb Id1 sequence obtained from pEM Id1 (kind gifts
of G. Condorelli, Kimmel Cancer Institute, Thomas Jefferson University,
Philadelphia, Pa.).
For detection of the myeloperoxidase mRNA level, cells were prepared
and seeded under the same conditions used for growth
analysis. At the
indicated time points, the cells were collected
and total RNA was
extracted as above. An 8-µg portion of total
RNA for each sample was
run on a 1% agarose-formaldehyde gel,
blotted onto a nitrocellulose
membrane, and hybridized with a
1.45-kb myeloperoxidase cDNA fragment
obtained from the pUC19-MMPO6
plasmid (a kind gift of Mauro Valtieri).
The cDNA probe was labeled
with [

-
32P]dCTP by the
random-primed DNA-labeling kit (Boehringer Mannheim)
and purified using
QuickSpinn G-50 Sephadex columns (Boehringer-Mannheim).
Western blots.
Cells were lysed with lysis buffer (50 mM
HEPES [pH 7.5], 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
10% glycerol, 1% NP-40, 100 mM NaF, 10 mM sodium pyrophosphate, 0.2 mM sodium orthovanadate; 1 mM phenylmethylsulfonyl fluoride, 10 µg of
aprotinin per ml). For the detection of DN Stat3 Y705F, 300 µg of
total extract was immunoprecipitated with an anti-FLAG antibody M2
(Sigma). After sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS PAGE) (4 to 15% polyacrylamide) and transfer, the
nitrocellulose membrane was probed with a monoclonal antibody against
Stat3 (Transduction Lab.). Phosphorylated Stat3 was detected by
immunoprecipitation or directly on whole lysates. For
immunoprecipitation, cells were washed three times with HBSS and
incubated in RPMI 1640 serum-free medium plus 0.1% bovine serum
albumin for 3 h before stimulation with 50 ng of IGF-I 50 per ml
(Gropep) for 2, 5, 30, or 60 min. The cells were collected, washed with
cold phosphate-buffered saline, and lysed with lysis buffer.
Portions (300 µg) of total extracts were immunoprecipitated
with an anti-Stat3 monoclonal antibody (Transduction Lab.) and the
precipitated proteins were separated by SDS-PAGE (4 to 15%
polyacrylamide). After transfer, the nitrocellulose membrane was probed
with a polyclonal antibody against antiphospho-Stat3 Y705 (New England
Biolabs). After being stripped, the membrane was probed with a
polyclonal antibody against Stat3 (Santa Cruz Biotechnology Inc.). For
detection on whole lysates, cells were washed three times with HBSS and
incubated in RPMI 1640 plus 10% FBS for 6 h before being
stimulated with 50 ng of IGF-I per ml for 5 or 30 min or with G-CSF
(Gibco, BRL) for 30 min. The cells were washed with phosphate-buffered
saline, suspended in hypertonic buffer (50 mM HEPES [pH 7.5], 250 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 0.1 mM
Na3VO4, 0.1% Tween 20, 10% glycerol, 1 mM
dithiothreitol, 0.1 mM phenyl methylsulfonyl fluoride, 10 µg of
Aprotinin per ml, 10 µg of leupeptin per ml, 10 µg of Pepstatin,
per ml), and lysed by freezing and thawing. Then 100 µg of lysate was
resolved by SDS-PAGE (4 to 15% polyacrylamide). After being blotted,
the membrane was probed with a polyclonal antibody against
antiphospho-Stat3 Y705 (New England Biolabs), stripped, and reprobed
with a Stat3 monoclonal antibody (Transduction Lab.).
For the activation and detection of Shc and Akt proteins, we have used
methods and antibodies described in previous papers
(
18,
44,
48). For extracellular signal regulated kinase
(ERK) activation,
cells were washed three times with HBSS and
incubated in serum-free
medium (SFM) for 3 h before being stimulated
with 50 ng of IGF-I
per ml at the indicated times. The cells were
lysed with lysis buffer
and 100 µg of total extracts was resolved
by SDS-PAGE (4 to 15%
polyacrylamide). ERK activation was detected
with anti-phospho
MAPK (Erk1/2) from UBI. The membrane was then
stripped and probed
with anti-Erk1 antibody, which recognizes
both Erk1 and Erk2 (Santa
Cruz Biotechnology, Inc., Santa Cruz,
Calif.). The same procedure was
used for the detection of Id proteins,
using antibodies from Santa
Cruz. The Grb2 antibody was from Transduction
Laboratories.
The phosphorylation of specific amino acids in p70
S6K
(phospho-Thr389) was detected with an antibody purchased from New
England
Biolabs. The total amount of p70
S6K loaded was
monitored after stripping of the filters by immunoblotting
with an anti
p70
S6K antibody (C-18; Santa
Cruz).
Tumor formation in nude mice.
The cell lines used are given
in Table 1. The procedure used was
exactly the same as the one described by Valentinis et al. (59).
 |
RESULTS |
As anticipated, a dominant negative mutant of Stat3 inhibited
IGF-I-mediated differentiation of 32D IGF-IR cells (see below). We
therefore investigated Id gene expression in 32D IGF-IR and 32D
IGF-IR/DNStat3 cells in the first 24 h after IL-3 withdrawal. We
limited ourselves to Id1 and Id2, because Id3 and Id4 are not expressed
in 32D cells (23).
Time course of Id gene expression after IGF-I stimulation.
After IL-3 withdrawal and IGF-I supplementation, Id2 mRNA levels were
increased. In 32D IGF-IR cells, there was a modest but reproducible
increase at 4 h after shifting to IGF-I. The increase in Id2 RNA
levels was much more dramatic in 32D IGF-IR/DNStat3 cells than in 32D
IGF-IR cells (Fig. 1A). There was another
peak at 4 h, but Id2 RNA levels were still quite high at 24 h. An important point is that Id2 mRNA levels in both cell lines were
higher when the cells were cultured in IGF-I than when they were
growing in IL-3. These experiments have been repeated several times,
with the same results (see also below). This observation is intriguing because in the first 48 h, 32D IGF-IR cells and 32D IGF-IR/DNStat3 cells doubled in number in each 24-h period, although their fates diverged soon after. The burst of cell proliferation that follows the
addition of IGF-I to 32D IGF-IR cells has been repeatedly documented in
previous papers (18, 48, 59) and was confirmed in the
present experiments (data not shown). The growth of 32D IGF-IR/DNStat3
in IGF-I-supplemented medium will be documented below. Furthermore, in
IL-3, all 32D-derived cell lines, even those with nonfunctional mutants
of the IGF-IR, grow exponentially (18, 48, 59, 60). The
results of Fig. 1A therefore indicate that the activated IGF-IR
up-regulates Id2 gene expression and that the dramatic up-regulation in
32D IGF-IR/DNStat3 cells does not solely reflect the proliferative
status of the cells. Finally, in the first 48 h, cell death in
these cell lines is negligible (reference 60 and data not
shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Time course of Id gene expression in 32D-derived cells.
The cell lines used were 32D IGF-IR and 32D IGF-IR/DNStat3. The
expression of the mRNAs for Id1 and Id2 was determined at the times
indicated after IL-3 withdrawal and supplementation with IGF-I. The
IL-3 lane refers to cells exponentially growing in IL-3. RNA and
Northern blots were prepared as described in Materials and Methods. (A)
mRNA levels of Id2. (B) mRNA levels of Id1. Levels of rRNA were used to
monitor RNA amounts in each lane. (C) Levels of Id proteins in the same
cell lines growing in IL-3 or 6 h after shifting to IGF-I. The
antibodies are described in Materials and Methods. Grb2 levels were
used to monitor the protein amounts in each lane.
|
|
The results with Id1 mRNA are inconclusive (Fig.
1B). There was a
modest increase in Id1 RNA levels in 32D IGF-IR/DNStat3
cells when
compared with the parental cell line, 32D IGF-IR cells.
Although the
increase was reproducible, it never was as impressive
as with Id2. In
addition, Id1 RNA levels were, in some experiments,
as high in IL-3 as
in IGF-I. The increase in Id2 RNA levels in
32D IGF-IR/DNStat3 cells
was accompanied by an increase in the
levels of Id2 protein (Fig.
1C).
Again, the results with Id1 protein
were inconclusive. These first
experiments indicated a relationship
between the IGF axis and the
expression of Id genes. Id2 gene
expression was dramatically increased
by IGF-I in 32D IGF-IR cells
expressing DNStat3. We next examined the
dependence of these changes
on signaling from the IGF-IR, focusing on
the Id2 RNA
levels.
Regulation of Id2 gene expression is IGF-I dependent.
32D
IGF-IR/DNStat3 cells were grown either in 10% serum or in serum
supplemented with IGF-I. It is clear that supplementation with IGF-I is
obligatory for the sustained growth of these cells in the absence of
IL-3 (Fig. 2A). We then determined Id
gene expression under the same conditions. A typical experiment is
shown in Fig. 2B, where we compared Id2 RNA levels in three different
cell lines: parental 32D cells, 32D IGF-IR cells, and 32D
IGF-IR/DNStat3 cells. The cells were incubated either in IL-3 or in
IGF-I (50 ng/ml) for 6 h. Id2 RNA was barely detectable in
parental 32D cells, and its level increased modestly in 32D IGF-IR
cells stimulated with IGF-I. It was markedly increased in 32D
IGF-IR/DNStat3 cells, especially when incubated with IGF-I. These
experiments indicate in 32D IGF-IR cells, the dramatic up-regulation of
Id2 mRNA requires both a dominant negative mutant of Stat3 and an
IGF-IR activated by its ligand. The IGF-IR requirement for the
proliferation of 32D IGF-IR/DNStat3 cells will be further documented
below. We asked at this point whether Id2 RNA up-regulation also
occurred in another cell line. For this experiment, we chose an NIH
3T3-like cell line of mouse embryo fibroblasts called R600 cells
(49). Figure 2C shows that the levels of Id2 mRNA were
very high in stimulated cells (lane 1) but undetectable in quiescent
cells (lane 2). Since activation of the IGF-IR is required for Id2
up-regulation in the 32D model, we next attempted to identify the
domain(s) of the receptor sending this signal.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
IGF-I is required for up-regulation of Id2 RNA and
inhibition of differentiation by DNStat3. (A) Growth of 32D IGF-IR/DN
Stat3 cells was determined in 10% serum in the presence or absence of
IGF-I (50 ng/ml). The results given were obtained at 96 h after IL-3
withdrawal. (B) Expression of Id2 mRNA in parental 32D cells, 32D
IGF-IR cells, and 32D IGF-IR/DNStat3. The cells were exponentially
growing either in IL-3 or in IGF-I, as indicated above the lanes. IGF-I
was added for 6 h. (C) Id2 mRNA levels in mouse embryo fibroblasts
(R600 cells). The cells were either quiescent (lane 2) or stimulated
(lane 1). RNA amounts in the last two panels were monitored with
rRNA.
|
|
Effect of a mutation at Y950 of the IGF-IR on IGF-I regulation of
Id2 RNA expression.
It is generally agreed that the main mitogenic
and antiapoptotic pathways of the IGF-IR largely depend on the
activation of one of its major substrates, IRS-1 (7, 64).
IRS-1, in turn, activates the PI3K/Akt pathway (19, 33, 34,
37). In 32D cells, which do not express IRS-1 (or IRS-2), the
mitogenic and antiapoptotic signals originating from the IGF-IR depend
on two other pathways (48). One of these pathways
originates from Y950 (18, 44), which is also involved in
IGF-I-mediated differentiation (60). Accordingly, we have
investigated the expression of Id mRNAs in four cell lines: 32D IGF-IR,
32D IGF-IR/DNStat3, 32D Y950F, and 32D Y950F/DNStat3. The 32D
IGF-IR/Y950F cell line has already been described (18, 44,
60). DNStat3 was transduced into these cells (see below for
expression levels). The cells were shifted from IL-3 to IGF-I, and the
mRNA levels were determined at the times indicated in Fig.
3. The results of a typical experiment are again different for the two Id mRNAs. We confirmed that the levels
of Id2 RNA were markedly increased in 32D IGF-IR/DNStat3 cells,
compared with the parental 32D IGF-IR cell line (Fig. 3A). However, the
results with the cells expressing the Y950F mutant receptor were very
different. No Id2 mRNA was detectable in these two cell lines, whether
expressing DNStat3 or not (Fig. 3B). This experiment was repeated three
times, and always yielded the same results. Id1 mRNA levels were again
somewhat higher in 32D IGF-IR/DNStat3 cells than in 32D IGF-IR cells
(Fig. 3A). However, Id1 gene expression was not really affected by a
mutation at Y950 (Fig. 3B). If anything, a mutation at Y950 actually
increased Id1 gene expression. This is an important control, because it
shows that the mutation at Y950 selectively abrogates Id2 gene
expression and that 32D Y950F/DNStat3 cells, at these times, are still
viable and in satisfactory condition.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of a mutation at Y950 of the IGF-I receptor on Id
gene expression. The same experiments described in the legend to Fig. 1
were carried out with four cell lines: 32D IGF-IR (A), 32D
IGF-IR/DNStat3 (A), 32D Y950F (B), and 32D Y950F/DNStat3 (B). Y950F
refers to a mutation in tyrosine 950 of the IGF-IR (see text). The
levels of Id1 and Id2 mRNA were determined at the indicated times (in
hours after shifting from IL-3 to IGF-I) as described in Materials and
Methods. The cell lines are indicated above the lanes (the amounts of
RNA in each lane are in the lower rows).
|
|
Mechanism of Y950 activation of Id2 gene expression.
Y950 of
the IGF-IR binds Shc proteins (13). Shc proteins are known
to activate the Ras-Raf-MAPK pathway (5, 56). We have
repeatedly shown that 32D IGF-IR cells with a mutation at Y950F have a
decreased MAPK activity (18, 44). However, it has recently
been reported that Shc phosphorylation may also activate the PI3K
pathway (26). In addition, IGF-I causes a modest but reproducible increase in PI3K activity in 32D IGF-IR cells, even in the
absence of IRS-1, an increase that is translated into an increase in
Akt activation (44, 60). To distinguish between these two
possibilities, we have used inhibitors of MAPK and PI3K to study their
effect on Id2 gene expression in 32D IGF-IR/DNStat3 cells. The results
are shown in Fig. 4. Again, there was a
sharp increase in Id2 RNA levels when 32D IGF-IR/DNStat3 cells were shifted from IL-3 to IGF-I. Both a MEK inhibitor (PD98059) and a PI3K
inhibitor (LY294002) effectively inhibited Id2 gene expression, indicating that both pathways are important for Id2 up-regulation.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 4.
Inhibitors of PI3K and ERK pathways inhibit
IGF-I-mediated up-regulation of Id2 RNA. The cell line examined was the
32D IGF-IR/DNStat3 cell line. The treatment and the times (in hours)
after IGF-I stimulation are indicated above the lanes. The first four
lanes refer to untreated cells. The other lanes refer to cells treated
with either PD98059 (MEK inhibitor) or LY294002 (PI3K inhibitor). RNA
and Northern blot analyses were carried out as for previous figures.
|
|
Shc phosphorylation and MAPK activation in 32D-derived cells.
The experiments in Fig. 3 indicate that in this model, Id2 gene
expression requires an intact Y950 residue. The literature (see
Discussion) strongly supports the notion that Y950 sends a signal
through Shc to the MAPK pathway. The effect of a MAPK inhibitor on Id2
gene expression suggests an involvement of MAPK in Id activation (Fig.
4). We have already reported that a mutation at Y950 of the IGF-IR
markedly decreases or even completely abrogates the phosphorylation of
the 52-kDa isoform of the Shc proteins in 32D IGF-IR cells (18,
44, 60). MAPK activity is also markedly decreased in 32D cells
expressing the Y950F receptor (18, 44, 48). We have
repeated these experiments and extended them to cells expressing
DNStat3. Not surprisingly, DNStat3 did not restore the inhibition of
Shc and MAPK activation in cells expressing the mutant receptor (Fig.
5).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Phosphorylation of Shc and ERKs in 32D-derived cells.
(A) The indicated cell lines were stimulated with IGF-I (50 ng/ml) for
10 min. Phosphorylated Shc proteins and Shc protein amounts were
determined as described in Materials and Methods. (B) MAPK activation
in 32D IGF-IR and 32D IGF-IR/DNStat3 cells. Above the lanes are the
times (in minutes) after stimulation with IGF-I. (C) Same experiment as
in panel B, but in the cell lines expressing the IGF-IR with a mutation
at Y950.
|
|
According to the experiments in Fig.
4, the PI3K pathway may also send
a signal for the activation of Id2 gene expression.
IGF-I activates Akt
in 32D IGF-IR cells, albeit at much decreased
levels compared to those
in cells expressing IRS-1 (
44,
60).
A mutation at Y950,
however, completely abrogates the modest activation
of Akt in these
cells (
44). Again, the expression of DNStat3
did not
restore the activation of Akt in 32D/Y950F cells (data
not shown). It
seems, therefore, that the failure of 32D cells
expressing the mutant
receptor to up-regulate Id2 gene expression
depends on the inability of
Y950F to activate the MAPK and PI3K
pathways (Fig.
4).
Activation of Stat3 by the IGF-IR.
The previous experiments
indicate that both Y950 and Stat3 play an important role in the
up-regulation of Id2 gene expression. Since DNStat3 inhibits
differentiation of 32D IGF-IR cells, it is reasonable to assume that
the IGF-IR activates Stat3 and that its activation is necessary for
their differentiation. We asked whether Stat3 would be activated in 32D
cells expressing the IGF-IR with a mutation at Y950. There are
already reports in the literature indicating that the IGF-IR
activates Stat3 (68, 69), although usually in association
with transformation rather than differentiation. We have investigated
the phosphorylation of tyrosine 705 (Y705) of Stat3 in 32D IGF-IR cells
and in 32D IGF-IR/DNStat3 cells (Fig. 6).
In the first experiment (Fig. 6A), lysates were immunoprecipitated with
an antibody to Stat3 and the gels were blotted with an antibody recognizing the phosphorylated Y705 residue. Y705 phosphorylation was
detectable in 32D IGF-IR cells between 30 and 60 min after stimulation
with IGF-I. Under the conditions used, Y705 phosphorylation was not
detectable in 32D IGF-IR/DNStat3 cells, presumably because the dominant
negative mutant interferes with its detection. In a second experiment,
Western blotting was done directly on lysates from the same cells (Fig.
6B). A Y705 phosphorylated Stat3 was again detectable in 32D IGF-IR
cells, with a slight increase already visible 5 min after IGF-I
stimulation. This band was not clearly detectable in 32D IGF-IR/DNStat3
cells, although there was more Stat3 protein in the lysates from these
cells (as expected). As a control, we used stimulation with G-CSF (Fig.
6B, right). In the presence of G-CSF, which is a strong activator of
Stat3, a band was also visible in 32D IGF-IR/DNStat3 cells, although
its intensity was decreased in comparison to that in 32D IGF-IR cells.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 6.
Phosphorylation of tyrosine 705 of Stat3 by IGF-I. The
cell lines are indicated above the panels. (A) The times (in minutes)
are times after placing the cells in serum-free medium (SFM) and
stimulation with IGF-I. The lysates were immunoprecipitated with an
antibody to Stat3, and the blots were developed with a phosphoantibody
to tyrosine 705 of Stat3. The blots were then reprobed with an antibody
to Stat3. (B) Western blots on lysates of the same cell lines. The
blots were probed directly with an antibody to Y705 (upper row) and
then reprobed with anti-Stat3 antibody (lower row). In the experiment
on the right, G-CSF was used as control for the phosphorylation of
Y705. (C) A mutation at Y950 of the IGF-IR abrogates the detection of
Y705 phosphorylation of Stat3, regardless of the presence or absence of
DNStat3 (left). The right panel shows that Y705 phosphorylation of
Stat3 is not abrogated in the same cell lines stimulated with G-CSF.
|
|
We have tested the activation of Stat3 in 32D cells expressing the
receptor mutated at Y950. The results are shown in Fig.
6C.
Phosphorylation of Stat3 at Y705 was no longer detectable
in 32D cells
expressing the mutant IGF-IR, regardless of IGF-I
stimulation or the
presence of DNStat3. The parental cells expressing
the Y950F receptor,
though, were still capable of phosphorylating
Y705 when stimulated with
G-CSF (Fig.
6C). These results are compatible
with a model in which
Y950 is required for the phosphorylation
of Stat3 at Y705. Failure to
activate Stat3 (for instance, with
DNStat3) resulted in up-regulation
of Id2 gene expression and
inhibition of
differentiation.
A dominant negative mutant of Stat3 inhibits IGF-I-mediated
differentiation and causes transformation of 32D IGF-IR cells.
Id
proteins play a role in differentiation and tumor development (see
Introduction), and DNStat3 has a dramatic effect on their expression,
especially of Id2. We have asked whether this strong up-regulation of
Id2 in 32D IGF-IR/DNStat3 cells correlates with their growth and
differentiation. As already reported, 32D IGF-IR cells differentiate
along the granulocytic pathway, provided that the medium is
supplemented with IGF-I (59, 60). This was confirmed in
the experiment in Fig. 7A. Expression of
a dominant negative mutant of Stat3 (DN/Stat3) in 32D IGF-IR cells
caused inhibition of differentiation (Fig. 7A). For clarity, we show in
Fig. 7A only the extent of differentiation on day 4 after shifting the
cells from IL-3 to IGF-I. Later days, however, were also monitored, and
differentiation in 32D IGF-IR/DNStat3 was essentially abrogated. The
inhibition of differentiation was accompanied by increased growth
rates, IL-3 independence (Fig. 7B), and malignant transformation. The
difference in growth between the 32D IGF-IR cells and 32D IGF-IR/DNStat3 cells was already evident at 48 h, and it became more pronounced at later times (Fig. 2A), when 32D IGF-IR cells began
to differentiate (60). Figure 7B also shows that the
transformation of 32D IGF-IR cells by DNStat3 (IL-3 independence) is
dependent on a functional IGF-IR. When DNStat3 was expressed in
parental 32D cells or in 32D cells overexpressing the insulin receptor, the cells remained IL-3 dependent and died rapidly in its absence. The
failure of DNStat3 to transform 32D cells overexpressing the insulin
receptor confirms previous results indicating that in the absence of
IRS-1, the insulin receptor cannot protect 32D cells from apoptosis
induced by IL-3 withdrawal (18, 48, 66). The expression of
DNStat3 in these cell lines is shown in the inset of Fig. 7B, lanes 1 to 3. Since DN/Stat3 carried a FLAG tag, it was immunoprecipitated with
an anti-FLAG antibody, and the protein was detected with an antibody to
Stat3. Stat3 was not detectable in parental 32D cells by this method
(lane 4) but was present (see above).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 7.
A dominant negative mutant of Stat3 inhibits
IGF-I-mediated differentiation and causes transformation of 32D IGF-IR
cells. 32D cells were transduced with the appropriate retroviral
vectors, and mixed populations were selected. (A) IGF-IR cells and 32D
IGF-IR/DN Stat3 cells were grown in medium supplemented with 10% serum
and either IL-3 or IGF-I. The percentage of differentiated cells is
indicated on the ordinate. In this experiment, the cells were fixed and
stained after 4 days in the indicated medium. The percentage of
differentiated cells was determined by standard methods
(60). (B) After withdrawal of IL-3, the cells were grown
in medium supplemented with 10% serum and either IGF-I or insulin at a
concentration of 50 ng/ml. The cells were counted 48 h after IL-3
withdrawal. The cell lines are indicated on the left of the figure.
32D, parental cells; 32D IR, cells overexpressing the insulin receptor;
32D IGF-IR, cells expressing increased levels of IGF-IR. DN/STAT3
indicates the same cell lines stably transduced with the dominant
negative mutant of Stat3. The inset shows levels of expression of
DN/Stat3, after immunoprecipitation with a FLAG antibody and blotting
with an anti-Stat3 antibody. Lanes of inset: 1, 32D/DN Stat3; 2, 32D
IR/DN Stat3; 3, 32D IGF-IR/DN Stat3; 4, parental 32D cells.
|
|
32D IGF-IR/DNStat3 cells are fully transformed. They can be passaged
indefinitely in the absence of IL-3, and they can form
tumors in nude
mice (Table
1). As already reported, the parental
cells, 32D IGF-IR
cells, cannot form tumors in nude mice (
59).
32D
IGF-IR/DNStat3 cells form tumors in SCID mice, as evidenced
by the
increase in the weights of livers and spleens. The spleen
is especially
enlarged, to about 10 times the weight of a normal
spleen. This is also
what we found previously with 32D IGF-IR/IRS1
cells (
59),
which were repeated in Table
1 for comparison.
It may be argued that
32D IGF-IR/IRS1 cells form larger tumors
than 32D IGF-IR/DNStat3 cells.
However, these latter cells also
colonize the livers and spleens of
injected mice. The pathology
is that of a leukemia, infiltrating both
liver and spleen, which
has been previously documented histologically
(
59).
The results therefore indicate that in 32D IGF-IR cells, expression of
DNStat3 inhibits IGF-I-mediated differentiation and
causes
IL-3-independence and malignant transformation. These effects
of
DNStat3, however, are dependent on the presence of a functional
IGF-IR.
This was confirmed in the following
experiments.
A mutation at tyrosine 950 of IGF-IR abrogates the proliferative
effect of DNStat3.
Given that Y950 is necessary for the
up-regulation of Id2 gene expression by the IGF-IR (Fig. 3), one would
expect that a mutation at Y950 should abrogate the ability of DNStat3
to transform 32D IGF-IR cells. As mentioned above, we transduced
DNStat3 into 32D cells expressing the Y950F mutant of the IGF-I
receptor. The expression of the transduced DNStat3 in this cell line is
shown in the inset of Fig. 8. Stat3 was
again indicated by using an antibody to the FLAG epitope, and therefore
the parental cells are negative. Both cell lines, parental 32D/Y950F
and 32D/Y950F/DNStat3 cells, grew very well in IL-3, as expected.
However, neither of these cell lines survived after IL-3 withdrawal,
not even when the medium was supplemented with IGF-I (Fig. 8). In fact,
the cells expressing DNStat3 and the mutant receptor were
indistinguishable from the parental cells expressing only the mutant
receptor (Fig. 8). This is dramatically different from the effect of
DNStat3 on 32D cells expressing the wild-type IGF-IR.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 8.
Effect of a mutation at Y950 on the growth of 32D IGF-IR
cells expressing DNStat3. The cell lines are indicated to the right of
the figure or above the lanes. Y950F is a mutation at tyrosine 950 of
the IGF-I receptor. This mutation has been previously described (see
the text). The cell number was determined after 48 h of incubation
in the medium indicated on the abscissa. The inset shows the level of
expression of DNStat3 in the new cell line.
|
|
These experiments indicate that expression of DNStat3 is not sufficient
for the transformation of 32D IGF-IR cells (and the
up-regulation of
Id2 gene expression). The proliferative stimulus
originates from the
IGF-IR, and the function of DNStat3 is to
extinguish the
differentiation program, which is simultaneously
implemented by the
IGF-IR. When Y950 is mutated, DNStat3 cannot
stimulate the
proliferation of 32D IGF-IR cells and cannot up-regulate
Id2 gene
expression.
Functional significance of Id2 gene expression in 32D cells.
Our results clearly indicate that the IGF-IR and Stat3 cooperate in
regulating the expression of Id2 RNA and proteins in 32D cells. We
therefore wanted to know the functional significance of this
regulation. Since Id proteins are involved in both proliferation and
differentiation of cells (see Introduction), we have investigated the
effect that blockade or overexpression of Id2 may have on either
proliferation or differentiation of 32D-derived cells.
Differentiation of 32D IGF-IR cells is a slow process that becomes
clearly evident only on day 4 after shifting from IL-3
to IGF-I
(
60). It is therefore not always possible to score
for
morphological differentiation the cell lines that die in the
first 24 to 48 h after IL-3 withdrawal and IGF-I supplementation.
However,
we and others (
59-61) have shown that cells programmed
for differentiation have increased levels of myeloperoxidase (MPO)
RNA
in the first 24 h, although the cells at that time are actively
proliferating (
62). Therefore, MPO RNA levels are an early
marker
of differentiation that indicates whether the cells have started
a differentiation program (
60,
61). We first confirmed
this
finding in experiments with 32D IGF-IR and 32D IGF-IR/DNStat3
cells (Fig.
9A). We measured MPO RNA
levels in these two cell
lines at 72 h after the shifting of cells from
IL-3 to IGF-I.
As expected, MPO RNA levels increased sharply in
differentiating
32D IGF-IR cells but remained low in 32D IGF-IR/DNStat3
cells.
These experiments suggest that Id2 gene expression plays a role
in the inhibition of differentiation (see also below). We then
asked
whether overexpression of Id2 in 32D IGF-IR cells would
affect either
the proliferation or the differentiation programs
or both. For this
purpose, we transduced a retroviral vector expressing
the human Id2
cDNA (see Materials and Methods) into 32D IGF-IR
cells. Its effect on
the growth of these cells is shown in Fig.
9B. 32D IGF-IR cells stably
overexpressing Id2 (see inset in Fig.
9C) do not transform. Actually,
they underwent apoptosis, beginning
at about 48 h after withdrawal
of IL-3. These results are in agreement
with those of Florio et al.
(
23), who reported that overexpression
of Id2 in parental
32D cells resulted in an acceleration of apoptosis
caused by IL-3
withdrawal. However, overexpression of Id2 protein
affects the
differentiation program of 32D IGF-IR cells. Since
the cells expressing
Id2 die more quickly, we determined the levels
of expression of MPO RNA
at 24 h after shifting from IL-3 to IGF-I.
The results are shown
in Fig.
9C. Again, IGF-I increased MPO RNA
levels in 32D IGF-IR cells
but failed to do so in 32D IGF-IR Id2
cells. It seems, therefore, that
overexpression of Id2 protein
can inhibit the differentiation program
of 32D IGF-IR cells but
has no effect on their survival.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 9.
MPO RNA levels in 32D-derived cells. The levels of MPO
RNA, a marker of differentiation, were measured in the indicated cell
lines. The MPO RNA levels are expressed as percentage of values in the
same cell lines growing in IL-3-supplemented medium. The cell lines
designated 32D IGF-IR and 32D IGF-IR/DNStat3 have been described in the
previous figures. 32D IGF-IR Id2 cells are two mixed populations of 32D
IGF-IR cells stably overexpressing Id2 (see Materials and Methods for
the retroviral vector used). (A) MPO RNA levels in 32D IGF-IR and 32D
IGF-IR/DNStat3 cells at 72 h after shifting from IL-3 to IGF-I.
(B) Survival of 32D IGF-IR and 32D IGF-IR Id2 cell lines at 72 h
after shifting from IL-3 to IGF-I (expressed as the percent decrease or
increase over the plated number). The inset shows expression of Id2
protein in the parental cell lines (lane 1) and in the two mixed
populations transduced with the Id2 retroviral vector (lanes 2 and 3).
(C) MPO RNA levels in 32D IGF-IR and 32D IGF-IR Id2 cells, growing for
24 h in either IL-3 or IGF-I. The Northern blots give two distinct
populations of 32D IGF-IR Id2 cells, selected separately at different
times. Amounts of RNA in each lane were monitored with rRNA.
|
|
To confirm the effect of Id2 gene expression on differentiation, we
have used a second approach, based on a previous paper,
in which we
showed that the mTOR-specific inhibitor, rapamycin
(
20),
induces the differentiation of 32D IGF-IR/IRS-1 cells
(
60). If rapamycin induces differentiation in these cells,
it
may also do so in 32D IGF-IR/DNStat3 cells, which behave like
32D
IGF-IR/IRS-1 cells, forming tumors in nude animals (reference
60 and results cited above). Indeed, rapamycin treatment
of
32D IGF-IR/DNStat3 cells inhibited their growth (Fig.
10A) and
induced differentiation (Fig.
10B).
Rapamycin inhibits the activation
of p70
S6K
(
20), which was confirmed (inset in Fig.
10C). If Id2
down-regulation
is necessary for differentiation, then Id2 gene
expression should
decrease in 32D IGF-IR/DNStat3 cells treated with
rapamycin. This
is what happened (Fig.
10C) when Id2 gene expression
was compared
in these cells with or without rapamycin treatment. The
levels
of Id2 RNA were essentially the same as in 32D IGF-IR cells
treated
with IGF-I (compare the IL-3 and IGF-I treatments in Fig.
2B).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 10.
Effect of rapamycin on 32D IGF-IR/DNStat3 cells. 32D
IGF-IR/DNStat3 cells were incubated in 10% FBS plus IGF-I only or plus
IGF-I and rapamycin (10 ng/ml). (A) Growth of cells, expressed as the
percent increase over the number of plated cells, at 72 h after
IL-3 withdrawal and IGF-I supplementation (plus or minus rapamycin).
(B) Percentage of differentiated cells under the same conditions. (C)
Id2 RNA levels in 32D IGF-IR/DNStat3 cells, plus or minus rapamycin, at
the indicated times after IL-3 withdrawal and IGF-I supplementation.
The inset shows activation of p70S6K Lanes: 1, unstimulated; 2, stimulated with IGF-I (20 ng/ml) for 20 min; 3, same
in the presence of rapamycin. Total protein is shown in the lower
row.
|
|
 |
DISCUSSION |
The novel findings in this communication can be summarized as
follows. (i) the IGF-IR, activated by its ligand, regulates Id2 gene
expression. When Stat3 activation is inhibited by a dominant negative
mutant of Stat3, IGF-I causes a dramatic increase in Id2 gene
expression. (ii) in 32D cells, which do not express IRS-1 (48,
62), the tyrosine residue at 950 of the IGF-IR plays an
important role in the regulation of Id2 gene expression. (iii) regulation of Id2 gene expression by Y950 is both positive (through MAPK and PI3K) and negative (through Stat3). (iv) Up-regulation by
IGF-I of Id2 gene expression inhibits the differentiation program of
32D IGF-IR cells. (v) the differentiation program of 32D IGF-IR cells
is also inhibited by overexpression of Id2. (vi) 32D IGF-IR/DNStat3 cells are actually transformed (tumor formation in nude mice). However,
the up-regulation of Id2 gene expression, by itself, is not sufficient
for transformation, since 32D IGF-IR Id2 cells do not survive
withdrawal of IL-3. It seems, therefore, that the Id2 protein can
regulate the differentiation program of 32D cells but requires other
factors for their transformation, factors that are provided by the
inhibition of Stat3.
As a corollary to these findings, we would like to formulate a
hypothesis that will be discussed in detail below. In 32D IGF-IR cells,
which do not express IRS-1 or IRS-2 (60, 62), the tyrosine 950 residue of the IGF-IR simultaneously sends two signals. One signal,
through the activation of Shc and the MAPK and PI3K pathways (22,
25, 64), induces Id2 gene expression and a proliferative program. At the same time, Y950 sends (through the activation of Stat3)
a signal which represses Id2 gene activation and promotes cell
differentiation. Inhibition of Stat3 by DNStat3 causes a marked
increase in Id2 gene expression and inhibition of the differentiation program, resulting in continuous proliferation and transformation. The
dual signal from Y950 is seemingly contradictory, but it has a
reasonable explanation. As already pointed out, 32D IGF-IR cells proliferate actively for the first 48 h after shifting from IL-3 to IGF-I. As is the case with other growth factors of hematopoietic cells (see Introduction), IGF-I sends two signals, with the
differentiation signal eventually prevailing.
While there is substantial information about the functions of the Id
proteins, little is known about the growth factors and the pathways of
signal transduction that regulate the expression of the Id genes. There
are reports that Id gene expression is up-regulated by serum
(28) and platelet-derived growth factor (10).
Id2 expression is induced by serum (38) and by cytokines that drive granulocytic differentiation (11). Our data
provide evidence that the activated IGF-IR regulates Id2 gene
expression. Addition of IGF-I is necessary for the increase in Id2 gene
expression, whether in 32D IGF-IR cells or 32D IGF-IR/DNStat3 cells.
Id2 RNA levels are actually increased, in the presence IGF-I, over the levels in IL-3-cultured cells, indicating that the up-regulation is not
simply the consequence of cell proliferation (see also below). A
mutation at Y950 of the IGF-IR abrogates the up-regulation of Id2 RNA,
even in 32D IGF-IR/DNStat3 cells, indicating that Y950 is required in
these cells for the up-regulation of Id2 gene expression. It also
confirms that the signal originates from the IGF-IR.
The expression of DNStat3 in 32D-derived cells is accompanied by
dramatic changes in their biological behavior. DNStat3 inhibits differentiation and causes malignant transformation of cells. DNStat3
is known to interfere with Stat3 signaling (9, 24, 42,
43). Stat3 is involved in cell differentiation (42, 43,
65), and the same dominant negative mutant of Stat3 we have used
in these experiments is known to effectively inhibit differentiation by
other growth factors (47, 50, 54, 56). Another interesting
biological change is the effect of a mutation at Y950 on the survival
of 32D cells. We have already reported that a Y950F mutant receptor no
longer protects 32D cells from apoptosis induced by IL-3 withdrawal
(18, 60). DNStat3, although inhibiting IGF-I-mediated
differentiation in 32D IGF-IR cells, cannot rescue 32D Y950F cells from
apoptosis. Clearly, in this model, both the differentiation and the
mitogenic and survival signals originate from the IGF-IR and, more
precisely, from Y950. The function of DNStat3 is to inhibit the
differentiation program while leaving intact the proliferation program
of the IGF-IR (59).
The role of Id2 in transformation and differentiation of 32D cells is
complex. Decreased Id2 gene expression correlates with cell
differentiation (see Introduction), and this has been confirmed in our
experiments in several ways. Blockade of Id2 gene expression by
rapamycin induces the activation of the differentiation program of
32D-derived cells, as evidenced by morphological differentiation. Conversely, the overexpression of Id2 protein in 32D IGF-IR cells inhibits the activation of the differentiation program (MPO RNA levels). However, for transformation (growth in IL-3-free medium), Id2
up-regulation is not sufficient. 32D IGF-IR cells stably overexpressing Id2 undergo apoptosis after IL-3 withdrawal, even when supplemented with IGF-I. Florio et al. (23) have reported that Id2
overexpression accelerates apoptosis in 32D cells. Although our 32D
IGF-IR/Id2 cells do not die as quickly (probably because of the
protective effect of the IGF-IR), they certainly are not IL-3
independent. Therefore, Id2 down-regulation seems to be important for
differentiation but Id2 up-regulation is not sufficient for
transformation. These findings clearly dissociate the effects of Id2 on
differentiation and transformation.
More uncertain is the identification of the pathways originating from
Y950 of the IGF-IR in the absence of IRS-1. Especially puzzling, as
already mentioned, are the apparently contradictory signals originating
from Y950. The Y950 residue is the main binding site for Shc proteins
(13, 58), but it also binds IRS-1 (13, 58)
and the Crk proteins (35), all of which could send
positive signals. We can rule out IRS-1 in our case, since it is not
expressed in 32D cells, but we cannot rule out the Crk proteins
(35). The fact that Shc phosphorylation is impaired in
cells expressing the Y950 mutant indicates a role of Shc proteins,
without excluding a possible participation of other transducing
molecules. Interestingly, both PD98059 (an inhibitor of MEK) and
LY294002 (an inhibitor of P13K) suppress Id2 activation in 32D
IGF-IR/DNStat3 cells. Apparently, both pathways are involved in the
up-regulation of Id2 gene expression. It is not the first time that
both pathways have been found to be required in 32D cells for
transformation. Neither overexpression of Ras nor overexpression of
IRS-1 can transform 32D cells, but the two combined cause malignant
transformation with tumor formation in mice (14). While
the MAPK and PI3K pathways seem to be involved in the up-regulation of
Id2 gene expression (Fig. 4), the IGF-IR must also send a signal to
repress Id2 gene expression. It is reasonable to connect the inhibitory
signal again to Y950 and its ability to activate Stat3. The IGF-IR is known to activate Stat3 by phosphorylation of Stat3 Y705 (68, 69), and this was confirmed to occur in our cells. A mutation at
Y950 of the IGF-IR inhibits phosphorylation of Stat3 at Y705 and
abrogates the ability of the IGF-IR to up-regulate Id2 gene expression
in 32D IGF-IR/DNStat3 cells. The fact that a dominant negative mutant
of Stat3 markedly increases IGF-IR-mediated activation of Id2 gene
expression clearly indicates that the inhibitory signal goes through
Stat3. Possible candidates for this inhibition are SOCS-1 or SOCS-3,
both of which have been related to IGF-IR signaling and Stat3
(68). SOCS proteins bind the insulin receptor at Y960, which is the homologue of Y950 of the IGF-IR (21). At this
point, it would be too speculative to discuss the respective merits of Shc, Crk, SOCS, PI3K, and MAPK in activating the two programs.
The results with Id1 RNA expression are much less dramatic. More
significantly, the Y950F mutation has no effect on Id1 gene expression.
It confirms the importance of Y950 in Id2 gene expression. This
discrepancy on the effect of IGF-I on Id1 and Id2 expression is not
unique (32, 57), especially in hematopoietic cells (12). Another slight discrepancy occurs with the results
of Ishiguro et al.(31), who correlated the levels of Id2
with differentiation of myeloid cells. The discrepancy may be more
apparent than real, since Id2 RNA levels do increase in differentiating
32D IGF-IR cells. The difference is that this increase is much more
pronounced when differentiation is inhibited by DN Stat3. We did not
address in this paper the link between the IGF-IR and Stat3, apparently through the JAK proteins, which has already been considered by other
investigators (27, 67, 68).
In conclusion, the present results show that Id2 gene expression is
regulated by the activated IGF-IR. In the absence of IRS-1, Y950 of the
IGF-IR sends contradictory signals, one for stimulation and one for
repression of Id2 gene expression. The negative effect on Id2
expression signals through Stat3 and correlates with differentiation of
cells. The positive signal uses both the PI3K and MAPK pathways and
correlates with proliferation. When the Stat3 signal is inhibited by a
dominant negative mutant of Stat3, only the proliferative stimulus
remains, Id2 RNA levels are very high, and the cells become permanently
IL-3 independent. However, Id2 up-regulation is not sufficient to
confer IL-3 independence to 32D cells. The implications of these
results are important. Evidence is accumulating that Id1 plays a role
in the growth of breast cancer cells (16, 17, 39) while
Id2 binds the retinoblastoma protein (30) and is activated
by the proto-oncogene N-myc in neuroblastoma cells
(38). Although our results do not directly correlate Id2 gene expression with transformation, given the importance of the IGF-IR
in the establishment and maintenance of the transformed phenotype
(3, 4), the link between the IGF-IR and the Id genes could
offer new insights into the processes of differentiation and malignant transformation.
 |
ACKNOWLEDGMENTS |
This work is supported by grants CA 56309 and CA 78890 from the
National Institutes of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Kimmel Cancer
Center, Thomas Jefferson University, 233 S. 10th St., 624 BLSB,
Philadelphia, PA 19107. Phone: (215) 503-4507. Fax: (215)
923-0249. E-mail: r_baserga{at}lac.jci.tju.edu.
 |
REFERENCES |
| 1.
|
Alani, R. M.,
J. Hasskari,
M. Grace,
M. C. Hernandez,
M. A. Israel, and K. Munger.
1999.
Immortalization of primary human keratinocytes by the helix-loop-helix protein. Id1.
Proc. Natl. Acad. Sci. USA
96:9637-9641[Abstract/Free Full Text].
|
| 2.
|
Barone, M. V.,
R. Pepperkok,
F. A. Peverali, and L. Philipson.
1994.
Id proteins control growth induction in mammalian cells.
Proc. Natl. Acad. Sci. USA
91:4985-4988[Abstract/Free Full Text].
|
| 3.
|
Baserga, R., and A. Morrione.
1999.
Differentiation and malignant transformation: two roads diverged in a wood.
J. Cell. Biochem.
32/33:68-75.
|
| 4.
|
Baserga, R.,
M. Prisco, and A. Hongo.
1999.
IGFs and cell growth, p. 329-353.
In
R. G. Rosenfeld, and C. T. Roberts, Jr. (ed.), The IGF system Humana Press, Totowa. N.J.
|
| 5.
|
Basu, T.,
P. H. Warne, and J. Downward.
1994.
Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor.
Oncogene
9:3483-3491[Medline].
|
| 6.
|
Benezra, R.,
R. L. Davis,
D. Lockshon,
D. L. Turner, and H. Weintraub.
1990.
The protein Id: a negative regulator of helix-loop-helix DNA binding proteins.
Cell
61:49-59[CrossRef][Medline].
|
| 7.
|
Blakesley, V. A.,
A. A. Butler,
A. P. Koval,
Y. Okubo, and D. LeRoith.
1999.
IGF-I receptor function: transducing the IGF-I signal into intracellular events, p. 143-163.
In
R. G. Rosenfeld, and C. T. Roberts, Jr. (ed.), The IGF system. Humana Press, Totowa, N.J.
|
| 8.
|
Brown, G.,
M. A. Choudhry,
J. Durham,
M. T. Drayson, and R. H. Michell.
1999.
Monocytically differentiating HL60 cells proliferate rapidly before they mature.
Exp. Cell Res.
253:511-518[CrossRef][Medline].
|
| 9.
|
Chaturvedi, P.,
S. Sharma, and P. Reddy.
1997.
Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs.
Mol. Cell. Biol.
17:3295-3304[Abstract].
|
| 10.
|
Christy, B. A.,
L. K. Saunders,
L. F. Lau,
N. G. Copeland,
N. A. Jenkins, and D. Mathans.
1991.
An Id-related helix-loop-helix protein encoded by a growth factor inducible gene.
Proc. Natl. Acad. Sci. USA
88:1815-1819[Abstract/Free Full Text].
|
| 11.
|
Cooper, C. L., and P. E. Newburger.
1998.
Differential expression of Id genes in multipotent myeloid progenitor cells: Id1 is induced by early- and late-acting cytokines while Id2 is selectively induced by cytokines that drive terminal granulocytic differentiation.
J. Cell. Biochem.
71:277-285[CrossRef][Medline].
|
| 12.
|
Cooper, C. L.,
G. Brady,
F. Bilia,
N. N. Iscove, and P. J. Quesenberry.
1997.
Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system.
Blood
89:3155-3165[Abstract/Free Full Text].
|
| 13.
|
Craparo, A.,
T. J. O'Neill, and T. A. Gustafson.
1995.
Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor-I receptor.
J. Biol. Chem.
270:15639-15643[Abstract/Free Full Text].
|
| 14.
|
Cristofanelli, B.,
B. Valentinis,
S. Soddu,
M. G. Rizzo,
A. Marchetti,
G. Bossi,
A. R. Morena,
M. Dews,
R. Baserga, and A. Sacchi.
2000.
Co-operative transformation of 32D cells by the combined expression of IRS-1 and v-Ha-Ras.
Oncogene
19:3245-3255[CrossRef][Medline].
|
| 15.
|
De Koning, J. P.,
A. A. Soede-Bobok,
A. C. Ward,
A. M. Schelen,
C. Antonissen,
D. van Leeuwen,
B. Lowenberg, and I. P. Touw.
2000.
Stat-3-mediated differentiation and survival of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27Kip1.
Oncogene
19:3290-3298[CrossRef][Medline].
|
| 16.
|
Desprez, P. Y.,
E. Hara,
M. J. Bissell, and J. Campisi.
1995.
Suppression of mammary epithelial cell differentiation by the helix-loop-helix protein Id-1.
Mol. Cell. Biol.
15:3398-3404[Abstract].
|
| 17.
|
Desprez, P. Y.,
C. Q Lin,
N. Thomasset,
C. J. Simpson,
M. J. Bissell, and J. Campisi.
1998.
A novel pathway for mammary epithelial cell invasion by the helix-loop-helix protein Id-1.
Mol. Cell. Biol.
18:4577-4588[Abstract/Free Full Text].
|
| 18.
|
Dews, M.,
M. Prisco,
F. Peruzzi,
G. Romano,
A. Morrione, and R. Baserga.
2000.
Domains of the IGF-I receptor required for the activation of extracellular signal-regulated kinases.
Endocrinology
141:1289-1300[Abstract/Free Full Text].
|
| 19.
|
Dudek, H.,
S. R. Datta,
T. F. Franke,
M. J. Birnbaum,
R. Yao,
G. M. Cooper,
R. A. Segal,
D. R. Kaplan, and M. E. Greenberg.
1997.
Regulation of neuronal survival by the serine-threonine protein kinase Akt.
Science
275:661-665[Abstract/Free Full Text].
|
| 20.
|
Dufner, A., and G. Thomas.
1999.
Ribosomal S6 kinase signaling and the control of translation.
Exp. Cell Res.
253:100-109[CrossRef][Medline].
|
| 21.
|
Emanuelli, B.,
P. Peraldi,
C. Filloux,
D. Sawka-Verhelle,
D. Hilton, and E. van Obberghen.
2000.
SOCS-3 is an insulin-induced negative regulator of insulin signaling.
J. Biol. Chem.
275:15985-15991[Abstract/Free Full Text].
|
| 22.
|
English, J.,
G. Pearson,
J. Wilsbacher,
J. Swantek,
M. Karandikar,
S. Xu, and M. H. Cobb.
1999.
New insights into the control of MAP kinase pathways.
Exp. Cell Res.
253:255-270[CrossRef][Medline].
|
| 23.
|
Florio, M.,
M. C. Hernandez,
H. Yang,
H. K. Shu,
J. L. Cleveland, and M. A. Israel.
1998.
Id2 promotes apoptosis by a novel mechanism independent of dimerization to basic helix-loop-helix factors.
Mol. Cell. Biol.
18:5435-5444[Abstract/Free Full Text].
|
| 24.
|
Garcia, R.,
C. L. Yu,
A. Hudnall,
R. Catlett,
K. L. Nelson,
T. Smithgall,
D. J. Fujita,
S. P. Ethier, and R. Jove.
1997.
Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.
Cell Growth Differentiation
8:1267-1276[Abstract].
|
| 25.
|
Garrington, T. P., and G. L. Johnson.
1999.
Organization and regulation of mitogen-activated protein kinase signaling pathways.
Curr. Opin. Cell Biol.
11:211-218[CrossRef][Medline].
|
| 26.
|
Gu, H.,
H. Maeda,
J. J. Moon,
J. D. Lord,
M. Yoakim,
B. H. Nelson, and B. G. Neel.
2000.
New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway.
Mol. Cell. Biol.
20:7109-7120[Abstract/Free Full Text].
|
| 27.
|
Gual, P.,
V. Baron,
V. Lequoy, and E. van Obberghen.
1998.
Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor 1 receptor.
Endocrinology
139:884-893[Abstract/Free Full Text].
|
| 28.
|
Hara, E.,
T. Yamaguchi,
H. Nojima,
T. Ide,
J. Campisi,
H. Okayama, and K. Oda.
1994.
Id related genes encoding HLH proteins are required for G1 progression and are repressed in senescent human fibroblasts.
J. Biol. Chem.
269:2139-2145[Abstract/Free Full Text].
|
| 29.
|
Hawley, R. G.,
F. H. Lieu,
A. Z. Fong, and T. S. Hawley.
1994.
Versatile retroviral vectors for potential use in gene therapy.
Gene Ther.
1:136-138[Medline].
|
| 30.
|
Iavarone, A.,
P. Garg,
A. Lasorella,
J. Hsu, and M. A. Israel.
1994.
The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein.
Genes Dev.
8:1270-1284[Abstract/Free Full Text].
|
| 31.
|
Ishiguro, A.,
K. S. Spirin,
M. Shioara,
A. Tobler,
A. F. Gombart,
M. A. Israel,
J. D. Norton, and H. P. Koeffler.
1996.
Id2 expression increases with differentiation of human myeloid cells.
Blood
87:5225-5231[Abstract/Free Full Text].
|
| 32.
|
Jen, Y.,
K. Manova, and R. Benezra.
1996.
Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis.
Dev. Dyn.
207:235-252[CrossRef][Medline].
|
| 33.
|
Kennedy, S. G.,
A. J. Wagner,
S. D. Conzen,
J. Jordan,
A. Bellacosa,
P. N. Tsichlis, and N. Hay.
1997.
The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.
Genes Dev.
11:701-713[Abstract/Free Full Text].
|
| 34.
|
Khwaja, A.,
P. Rodriguez-Viciana,
S. Wennstrom,
P. H. Warne, and J. Downward.
1997.
Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/AAkt cellular survival pathway.
EMBO J.
16:2783-2793[CrossRef][Medline].
|
| 35.
|
Koval, A. P.,
V. A. Blakesley,
C. T. Roberts, Jr.,
V. Zick, and D. LeRoith.
1998.
Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor 1 receptor.
Biochem. J.
330:923-932.
|
| 36.
|
Kreider, B. L.,
R. Benezra,
G. Rovera, and T. Kadesch.
1992.
Inhibition of myeloid differentiation by the helix-loop-helix protein Id.
Science
255:1700-1702[Abstract/Free Full Text].
|
| 37.
|
Kulik, G., and M. J. Weber.
1998.
Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor 1.
Mol. Cell. Biol.
18:6711-6718[Abstract/Free Full Text].
|
| 38.
|
Lasorella, A.,
M. Noseda,
M. Beyna, and A. Iavarone.
2000.
Id2 is a retinoblasoma protein target and mediates signaling by Myc oncoproteins.
Nature
407:592-598[CrossRef][Medline].
|
| 39.
|
Lin, C. Q.,
J. Singh,
K. Murata,
Y. Itahana,
S. Parrinello,
S. H. Liang,
C. E. Gillett,
J. Campisi, and P. Y. Desprez.
2000.
A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells.
Cancer Res.
60:1332-1340[Abstract/Free Full Text].
|
| 40.
|
Lister, J.,
W. C. Forrester, and M. H. Baron.
1995.
Inhibition of an erythroid differentiation switch by the helix-loop-helix protein Id1.
J. Biol. Chem.
270:17939-17946[Abstract/Free Full Text].
|
| 41.
|
Lyden, D.,
A. Z. Young,
D. Zagzag,
W. Yan,
R. O'Reilly,
B. L. Bader,
R. O. Hynes,
Y. Zhuang,
K. Manova, and R. Benezra.
1999.
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.
Nature
401:670-677[CrossRef][Medline].
|
| 42.
|
Minami, M.,
M. Inoue,
S. Wei,
K. Takeda,
M. Matsumoto,
D. Kishimoto, and S. Akira.
1996.
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line.
Proc. Natl. Acad. Sci. USA
93:3963-3966[Abstract/Free Full Text].
|
| 43.
|
Nakajima, K.,
Y. Yamanaka,
K. Nakae,
H. Kojima,
M. Ichiba,
N. Kiuchi,
T. Kitaoka,
T. Fukada,
M. Hibi, and T. Hirano.
1996.
A central role of Stat3 on IL-6-induced regulation of growth and differentiation in M1 leukemia cells.
EMBO J.
15:3651-3658[Medline].
|
| 44.
|
Navarro, M., and R. Baserga.
2001.
Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor.
Endocrinology
142:1073-1081[Abstract/Free Full Text].
|
| 45.
|
Nickoloff, B. J.,
V. Chaturvedi,
P. Bacon,
J. Z. Qin,
M. F. Denning, and M. O. Diaz.
2000.
Id-1 delays senescence but does not immortalize keratinocytes.
J. Biol. Chem.
275:27501-27504[Abstract/Free Full Text].
|
| 46.
|
Norton, J. D.,
R. W. Deed,
G. Craggs, and F. Sablitzky.
1998.
Id helix-loop-helix proteins in cell growth and differentiation.
Trends Cell Biol.
8:58-65[CrossRef][Medline].
|
| 47.
|
Nosaka, T.,
T. Kawashima,
K. Misawa,
K. Ikuta,
A. L. F. Mui, and T. Kitamura.
1999.
STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.
EMBO J.
18:4754-4765[CrossRef][Medline].
|
| 48.
|
Peruzzi, F.,
M. Prisco,
M. Dews,
P. Salomoni,
E. Grassilli,
G. Romano,
B. Calabretta, and R. Baserga.
1999.
Multiple signaling pathways of the IGF-I receptor in protection from apoptosis.
Mol. Cell. Biol.
19:7203-7215[Abstract/Free Full Text].
|
| 49.
|
Prisco, M.,
G. Romano,
F. Peruzzi,
B. Valentinis, and R. Baserga.
1999.
Insulin and IGF-I receptor signaling in protection from apoptosis.
Horm. Metab. Res.
31:80-89[Medline].
|
| 50.
|
Raz, R.,
C. K. Lee,
L. A. Cannizzaro,
P. D'Eustachio, and D. E. Levy.
1999.
Essential role of STAT3 for embryonic stem cell pluripotency.
Proc. Natl. Acad. Sci. USA
96:2846-2851[Abstract/Free Full Text].
|
| 51.
|
Rodriguez-Tarduchy, G.,
M. K. L. Collins,
I. Garcia, and A. Lopez-Rivas.
1992.
Insulin-like growth factor I inhibits apoptosis in IL-3 dependent hemopoietic cells.
J. Immunol.
149:535-540[Abstract].
|
| 52.
|
Sasaoka, T.,
B. Draznin,
J. W. Leitner,
W. J. Langlois, and J. M. Olefsky.
1994.
Shc is the predominant signaling molecule coupling insulin receptors to activation of guanine nucleotide releasing factor and p21ras-GTP formation.
J. Biol. Chem.
269:10734-10738[Abstract/Free Full Text].
|
| 53.
|
Scher, C. D.,
R. C. Shephard,
H. N. Antoniades, and C. D. Stiles.
1979.
Platelet derived growth factor and the regulation of the mammalian fibroblast cell cycle.
Biochim. Biophys. Acta
560:217-241[Medline].
|
| 54.
|
Shimozaki, K.,
K. Nakajima,
T. Hirano, and S. Nagata.
1997.
Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells.
J. Biol. Chem.
272:25184-25189[Abstract/Free Full Text].
|
| 55.
|
Soon, L.,
L. Flechner,
J. S. Gutkind,
L. H. Wang,
R. Baserga,
J. H. Pierce, and W. Li.
1999.
Insulin-like growth factor 1 synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression.
Mol. Cell. Biol.
19:3816-3828[Abstract/Free Full Text].
|
| 56.
|
Steinman, R. A., and A. Iro.
1999.
Suppression of G-CSF-mediated Stat signalling by IL-3.
Leukemia
13:54-61[CrossRef][Medline].
|
| 57.
|
Sun, X. H.,
N. G. Copeland,
N. A. Jenkins, and D. Baltimore.
1991.
Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins.
Mol. Cell. Biol.
11:5603-5611[Abstract/Free Full Text].
|
| 58.
|
Tartare-Deckert, S.,
D. Sawka-Verhelle,
J. Murdaca, and van E. Obberghen.
1996.
Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.
J. Biol. Chem.
271:23456-23460.
|
| 59.
|
Valentinis, B.,
M. Navarro,
T. Zanocco-Marani,
P. Edmonds,
J. McCormick,
A. Morrione,
A. Sacchi,
G. Romano,
K. Reiss, and R. Baserga.
2000.
Insulin receptor substrate-1, p70S6K and cell size in transformation and differentiation of hemopoietic cells.
J. Biol. Chem.
275:25451-25459[Abstract/Free Full Text].
|
| 60.
|
Valentinis, B.,
G. Romano,
F. Peruzzi,
A. Morrione,
M. Prisco,
S. Soddu,
B. Cristofanelli,
A. Sacchi, and R. Baserga.
1999.
Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways.
J. Biol. Chem.
274:12423-12430[Abstract/Free Full Text].
|
| 61.
|
Valtieri, M.,
D. J. Tweardy,
D. Caracciolo,
K. Johnson,
F. Mavilio,
S. Altmann,
D. Santoli, and G. Rovera.
1987.
Cytokine dependent granulocytic differentiation.
J. Immunol.
138:3829-3835[Abstract].
|
| 62.
|
Wang, L. M.,
M. G. Myers, Jr.,
X. J. Sun,
S. A. Aaronson,
M. White, and J. H. Pierce.
1993.
IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hemopoietic cells.
Science
261:1591-1594[Abstract/Free Full Text].
|
| 63.
|
Ward, A. C.,
L. Smith,
J. P. de Koning,
Y. van Aesch, and I. P. Touw.
1999.
Multiple signals mediate proliferation, differentiation and survival from the granulocyte-colony stimulating factor receptor in myeloid 32D cells.
J. Biol. Chem.
274:14956-14962[Abstract/Free Full Text].
|
| 64.
|
White, M. F.
1998.
The IRS-signalling system: a network of docking proteins that mediate insulin action.
Mol. Cell. Biochem.
182:3-11[CrossRef][Medline].
|
| 65.
|
Wu, Y. Y., and R. A. Bradshaw.
2000.
Activation of Stat3 signaling pathway is required for differentiation by interleukin-6 in OC12-E2 cells.
J. Biol. Chem.
275:2147-2156[Abstract/Free Full Text].
|
| 66.
|
Yenush, L.,
C. Zanella,
T. Uchida,
D. Bernal, and M. F. White.
1998.
The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin.
Mol. Cell. Biol.
18:6784-6794[Abstract/Free Full Text].
|
| 67.
|
Zhang, V.,
J. Turkson,
C. Carter-Su,
T. Smithgall,
A. Levitzki,
A. Kraker,
J. J. Krolewski,
P. Medveczky, and R. Jove.
2000.
Activation of Stat3 in v-src transformed fibroblasts requires cooperation of Jak1 kinase activity.
J. Biol. Chem.
275:24935-24944[Abstract/Free Full Text].
|
| 68.
|
Zong, C. S.,
J. Chan,
D. E. Levy,
C. Horvath,
H. B. Sadowski, and L. H. Wang.
2000.
Mechanism of STAT3 activation by insulin-like growth factor I receptor.
J. Biol. Chem.
275:15099-15105[Abstract/Free Full Text].
|
| 69.
|
Zong, C. S.,
L. Zong,
Y. Jiang,
H. B. Sadowski, and L. H. Wang.
1998.
Stat3 plays an important role in oncogenic ros- and insulin-like growth factor 1 receptor-induced anchorage-independent growth.
J. Biol. Chem.
273:28065-28072[Abstract/Free Full Text].
|
Molecular and Cellular Biology, August 2001, p. 5447-5458, Vol. 21, No. 16
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.16.5447-5458.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shi, B., Sepp-Lorenzino, L., Prisco, M., Linsley, P., deAngelis, T., Baserga, R.
(2007). Micro RNA 145 Targets the Insulin Receptor Substrate-1 and Inhibits the Growth of Colon Cancer Cells. J. Biol. Chem.
282: 32582-32590
[Abstract]
[Full Text]
-
Zhu, X., Lin, Y., Bacanamwo, M., Chang, L., Chai, R., Massud, I., Zhang, J., Garcia-Barrio, M. T., Thompson, W. E., Chen, Y. E.
(2007). Interleukin-1 {beta}-induced Id2 gene expression is mediated by Egr-1 in vascular smooth muscle cells. Cardiovasc Res
76: 141-148
[Abstract]
[Full Text]
-
Kebebew, E., Peng, M., Treseler, P. A., Clark, O. H., Duh, Q.-Y., Ginzinger, D., Miner, R.
(2004). Id1 Gene Expression Is Up-Regulated in Hyperplastic and Neoplastic Thyroid Tissue and Regulates Growth and Differentiation in Thyroid Cancer Cells. J. Clin. Endocrinol. Metab.
89: 6105-6111
[Abstract]
[Full Text]
-
Sun, H., Baserga, R.
(2004). Deletion of the Pleckstrin and Phosphotyrosine Binding Domains of Insulin Receptor Substrate-2 Does Not Impair Its Ability to Regulate Cell Proliferation in Myeloid Cells. Endocrinology
145: 5332-5343
[Abstract]
[Full Text]
-
Prisco, M., Maiorana, A., Guerzoni, C., Calin, G., Calabretta, B., Voit, R., Grummt, I., Baserga, R.
(2004). Role of Pescadillo and Upstream Binding Factor in the Proliferation and Differentiation of Murine Myeloid Cells. Mol. Cell. Biol.
24: 5421-5433
[Abstract]
[Full Text]
-
Murphy, D. J., Swigart, L. B., Israel, M. A., Evan, G. I.
(2004). Id2 Is Dispensable for Myc-Induced Epidermal Neoplasia. Mol. Cell. Biol.
24: 2083-2090
[Abstract]
[Full Text]
-
Shen, Y., Schlessinger, K., Zhu, X., Meffre, E., Quimby, F., Levy, D. E., Darnell, J. E. Jr.
(2004). Essential Role of STAT3 in Postnatal Survival and Growth Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation. Mol. Cell. Biol.
24: 407-419
[Abstract]
[Full Text]
-
Sciacca, L., Prisco, M., Wu, A., Belfiore, A., Vigneri, R., Baserga, R.
(2003). Signaling Differences from the A and B Isoforms of the Insulin Receptor (IR) in 32D Cells in the Presence or Absence of IR Substrate-1. Endocrinology
144: 2650-2658
[Abstract]
[Full Text]
-
Prisco, M., Santini, F., Baffa, R., Liu, M., Drakas, R., Wu, A., Baserga, R.
(2002). Nuclear Translocation of Insulin Receptor Substrate-1 by the Simian Virus 40 T Antigen and the Activated Type 1 Insulin-like Growth Factor Receptor. J. Biol. Chem.
277: 32078-32085
[Abstract]
[Full Text]
-
Shen, W.-H., Zhou, J.-H., Broussard, S. R., Freund, G. G., Dantzer, R., Kelley, K. W.
(2002). Proinflammatory Cytokines Block Growth of Breast Cancer Cells by Impairing Signals from a Growth Factor Receptor. Cancer Res.
62: 4746-4756
[Abstract]
[Full Text]
-
Navarro, M., Valentinis, B., Belletti, B., Romano, G., Reiss, K., Baserga, R.
(2001). Regulation of Id2 Gene Expression by the Type 1 IGF Receptor and the Insulin Receptor Substrate-1. Endocrinology
142: 5149-5157
[Abstract]
[Full Text]